Immunohistochemical characterization of a monoclonal antibody detecting an endometrioid ovarian cancer-associated antigen

F R Giancotti, Giancotti FR, B H Dorsett, Dorsett BH, Kim KT, K T Kim, H L Ioachim, Ioachim HL, H R Barber, Barber HR
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 1990 · doi:10.1097/00004347-199007000-00005 · PMID:2197240
other OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-25 · read from full text ⓘ

The researchers developed a murine monoclonal antibody designated FEN-1 by immunizing mice with an antigen purified from endometrioid ovarian cancer ascites. Immunohistochemical analysis demonstrated that this IgG3 antibody specifically reacts with 100% of endometrioid ovarian cancers containing adenoacanthoma in paraffin-embedded tissues. The study explicitly noted that the antibody showed no reactivity against endometriosis, normal ovary, normal endometrium, or various other tumor types, confirming its specificity for the target malignancy. This paper is centrally about endometriosis — specifically, it cites endometriosis as a condition where the tested antibody shows no cross-reactivity, thereby helping to distinguish endometrioid ovarian carcinoma from benign endometriotic tissue.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Murine monoclonal antibody FEN-1 was derived by immunizing Balb/c mice with an affinity-purified endometrioid ovarian cancer-associated antigen recovered from ascites-derived immune complexes. Splenic lymphocytes from the immunized mouse were fused with the myeloma cells SP2/0-AG14 in the presence of PEG 1500. The hybrid cultures were screened for production of immunoglobulins reactive with an extract preparation of an endometrioid ovarian tumor by enzyme-linked immunosorbent assay and flow cytometry. One of the hybrids secretes a monoclonal antibody of the IgG3 subtype designated FEN-1, which reacts with 100% of endometrioid ovarian cancer containing adenoacanthoma by indirect immunoperoxidase on paraffin-embedded tissue. No detectable levels of antigen were found in squamous metaplasia associated with nonendometrioid tumors, and no reactivity occurred against endometrial adenocarcinomas, endometriosis, or normal ovary and endometrium. The antibody does not cross-react with mucinous tumors, nonepithelial tumors of the ovary, or gastrointestinal tissue. This antibody may be used as an aid in the diagnosis of nonmucinous ovarian carcinomas by immunohistology.
Full text 1,406 characters · extracted from oa-doi-fallback · click to expand
Immunohistochemical Characterization of a Monoclonal Antibody Detecting an Endometrioid Ovarian Cancer-Associated Antigen - Francesca R. Giancotti - Brent H. Dorsett - Kyung Tai Kim - Harry L. Ioachim - Hugh R. K. Barber Summary: Murine monoclonal antibody FEN-1 was derived by immunizing Balb/c mice with an affinity-purified endometrioid ovarian cancer–associated antigen recovered from ascites-derived immune complexes. Splenic lymphocytes from the immunized mouse were fused with the myeloma cells SP2/0–AG14 in the presence of PEG 1500. The hybrid cultures were screened for production of immunoglobulins reactive with an extract preparation of an endometrioid ovarian tumor by enzyme-linked immunosorbent assay and flow cytometry. One of the hybrids secretes a monoclonal antibody of the IgG3 subtype designated FEN-1, which reacts with 100% of endometrioid ovarian cancer containing adenoacanthoma by indirect immunoperoxidase on paraffin-embedded tissue. No detectable levels of antigen were found in squamous metaplasia associated with nonendometrioid tumors, and no reactivity occurred against endometrial adenocarcinomas, endometriosis, or normal ovary and endometrium. The antibody does not cross-react with mucinous tumors, nonepithelial tumors of the ovary, or gastrointestinal tissue. This antibody may be used as an aid in the diagnosis of nonmucinous ovarian carcinomas by immunohistology.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Antibodies, Monoclonal Antibodies, Monoclonal Antibodies, Monoclonal Antigens, Neoplasm Immunohistochemistry Ovarian Neoplasms Animals Antigens, Neoplasm Antigens, Neoplasm Endometrium Enzyme-Linked Immunosorbent Assay Female Flow Cytometry Fluorescent Antibody Technique Hybridomas Immunization Immunoenzyme Techniques Mice Mice, Inbred BALB C Ovarian Neoplasms

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-31T06:09:41.840111+00:00
pubmed
last seen: 2026-05-13T22:12:15.619952+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine